Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
U.K. Cancer Institute Links With AstraZeneca
May 26, 2008
| A version of this story appeared in
Volume 86, Issue 21
Cancer Research Technology, the development and commercialization arm of the nonprofit Cancer Research UK, has signed on AstraZeneca as the first partner in its clinical development program. As part of the deal, CRT will put AstraZeneca's tyrosine-kinase inhibitor AZD0424 into Phase I trials within the next 18 months. The program aims to revive shelved cancer agents by conducting early-phase clinical trials at no cost to partner companies that retain rights to the drug. CRT will receive a share of any revenues should the drug make it to market. CRT's goal is to double the number of trials it conducts over the next five years.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X